Effect of saxagliptin on cognitive function in patients with type 2 diabetes after ischemic stroke

doi:10.3969/j.issn.1006-7795.2019.05.010

Abstract

Abstract: Objective To investigate the effect of saxagliptin on cognitive function in patients with ischemic stroke and type 2 diabetes.Methods This is a prospective cohort study. A total of 255 new ischemic stroke patients combined with type 2 diabetes were randomly divided into two groups, saxagliptin group and non-saxagliptin group (intervened with gliclazide). Demographic characteristics and basic biochemistry data were collected. The initial cognitive function was evaluated by Montreal Cognitive Assessment (MoCA). The participants with MoCA score below 26 and/or serum glucose disqualified were excluded. Totally 206 patients were screened, and cognitive function assessment was re-evaluated at 1, 3, and 5 months after stroke. The score below 22 points was set as the end point event, which was defined as post-stroke cognitive impairment (PSCI). MoCA scores between the two groups were analyzed with multivariate COX regression analysis.Results Totally 130 cases complete this research. Baseline data were compared between the two groups and no statistical differences were observed. At the end of the observation, 37 patients in the saxagliptin group reached the end point (62 analyzed), with the incidence of PSCI 59.7%, and 50 patients in the non-saxagliptin group reached the end point (68 analyzed), with the incidence of PSCI 73.5%. Multivariate COX regression analysis suggested that the hazard ratio (HR) for saxagliptin intervention was 0.617, with 95%CI 0.388~0.983 and P<0.05.Conclusion Saxagliptin hypoglycemic therapy can reduce the degree of PSCI in patients with ischemic stroke complicated with type 2 diabetes. Conclusion Saxagliptin hypoglycemic therapy can reduce the degree of PSCI in patients with ischemic stroke complicated with type 2 diabetes.

Key words: cognitive function, stroke, post-stroke cognitive impairment, diabetes, saxagliptin

CLC Number:

Li Sen, Huang Anqi, Guo Jianfei, Bai Jie, Zhang Guangzhen, Wang Ting, Zhao Yongmei. Effect of saxagliptin on cognitive function in patients with type 2 diabetes after ischemic stroke[J]. Journal of Capital Medical University, 2019, 40(5): 715-720.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.05.010

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I5/715

References

[1] Mijajlović M D, Pavlović A, Brainin M, et al. Post-stroke dementia-a comprehensive review[J]. BMC Med, 2017,15(1):11-22.
[2] 董强, 郭起浩, 罗本燕, 等. 卒中后认知障碍管理专家共识[J]. 中国卒中杂志, 2017,12(6):519-531.
[3] Lim J S, Kim C, Oh M S, et al. Effects of glycemic variability and hyperglycemia in acute ischemic stroke on post-stroke cognitive impairments[J]. J Diabetes Complications, 2018,32(7):682-687.
[4] Duarte A I, Candeias E, Correia S C, et al. Crosstalk between diabetes and brain:glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration[J]. Biochim Biophys Acta, 2013,1832(4):527-541.
[5] Hackett M L, Pickles K. Part I:frequency of depression after stroke:an updated systematic review and meta-analysis of observational studies[J]. Int J Stroke, 2014,9(8):1017-1025.
[6] Dichgans M, Leys D. Vascular cognitive impairment[J]. Circ Res, 2017,120(3):573-591.
[7] 黎洁洁, 彭玉晶, 王拥军. 早期二甲双胍治疗对糖尿病前期合并短暂局灶脑缺血后长期认知功能的影响[J]. 中国卒中杂志, 2018,13(8):834-839.
[8] Cimini A, Cerù M P. Emerging roles of peroxisome proliferator-activated receptors (PPARs) in the regulation of neural stem cells proliferation and differentiation[J]. Stem Cell Rev, 2008,4(4):293-303.
[9] Zanotto C, Simão F, Gasparin M S, et al. Exendin-4 reverses biochemical and functional alterations in the blood-brain and blood-CSF barriers in diabetic rats[J]. Mol Neurobiol, 2016,54(3):2154-2166.
[10] 虎子颖,张会峰,汪艳芳. 利格列汀对老年2型糖尿病患者轻度认知功能障碍的影响及机制研究[J]. 中华老年医学杂志, 2018,37(10):1069-1072.
[11] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志,2018,10(1):4-67.
[12] 中华医学会神经病学分会.中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.
[13] Lees R, Selvarajah J, Fenton C, et al. Test accuracy of cognitive screening tests for diagnosis of dementia and multidomain cognitive impairment in stroke[J]. Stroke, 2014,45(10):3008-3018.
[14] Wang Q, Zhao K, Cai Y, et al. Prediabetes is associated with post-stroke cognitive impairment in ischaemic stroke patients[J]. Brain Res, 2018,1687:137-143.
[15] Umarova R M, Sperber C, Kaller C P, et al. Cognitive reserve impacts on disability and cognitive deficits in acute stroke[J]. J Neurol, 2019,June 28. doi:10.1007/S00415-019-09442-6.[Epub ahead of print].
[16] Rhea E M, Banks W A. Role of the blood-brain barrier in central nervous system insulin resistance[J]. Front Neurosci, 2019,13:521-534.
[17] de la Monte S M. Insulin resistance and neurodegeneration:progress towards the development of new therapeutics for alzheimer's disease[J]. Drugs, 2017,77(1):47-65.
[18] Bergmann N C, Lund A, Gasbjerg L S, et al. Effects of combined GIP and GLP-1 infusion onenergy intake, appetite and energy expenditure in overweight/obese individuals:a randomised, crossover study[J]. Diabetologia, 2019,62(4):665-675.
[19] Jensterle M, Janez A, Fliers E, et al. The role of glucagon-like peptide-1 in reproduction:from physiology to therapeutic perspective[J]. Hum Reprod Update, 2019,25(4):504-517.
[20] Mcclean P L, Parthsarathy V, Faivre E, et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease[J]. J Neurosci, 2011,31(17):6587-6594.
[21] Lennox R, Flatt P R, Gault V A. Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice[J]. Peptides, 2014,61:38-47.
[22] Perry T, Lahiri D K, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron[J]. J Neurosci Res, 2003,72(5):603-612.
[23] Nakaoku Y, Saito S, Yamamoto Y, et al. The dipeptidyl peptidase-4 inhibitor linagliptin ameliorates high-fat induced cognitive decline in tauopathy model mice[J]. Int J Mol Sci, 2019,20(10):pii:E2539.
[24] Hardigan T, Abdul Y, Ergul A. Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes[J]. Life Sci, 2016,159:90-96.
[25] Gault V A, Lennox R, Flatt P R. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline[J]. Diabetes Obes Metab, 2015,17(4):403-413.